Nervous System News and Research

Latest Nervous System News and Research

Black women with high blood pressure during pregnancy have higher homocysteine levels

Black women with pregnancy-induced high blood pressure have more homocysteine (an amino acid linked with atherosclerosis) and less folic acid in their blood than white women.

19 Apr 2004

Chinese mushrooms can improve physical well-being

Nutritionists have since joined with manufacturers to produce supplements using fermentation from this rare mushroom. One such product is CordyMax®, made with a formula recognized in China as the fermented Cordyceps mushroom mycelial product. CordyMax® has been placed under intellectual property protection, and only one company has the license for it outside of China.

19 Apr 2004

Curry offers possible protection against Alzheimer’s disease

A new study has found that curry, a common and popular cooking additive, could be an effective enhancer of an enzyme that protects the brain against oxidative conditions.

19 Apr 2004

Using mass spectrometry to diagnose cancers and non-cancerous diseases

Using mass spectrometry, Emory University scientists have identified specific protein fingerprints in the cerebrospinal fluid (CSF) of humans that enable them to differentiate between cancers, both primary and metastatic, and non-cancerous diseases of the central nervous system (CNS).

18 Apr 2004

Omega-3 fatty acids found in seafood improve brain function

Citing new evidence that the omega-3 fatty acids found in seafood improve brain function in middle aged people and actually lower the risk of mental impairment as people age, the U.S. Tuna Foundation (USTF) today reminded the public that canned tuna is not only good for your heart but is a tasty and affordable "brain food" for people of all ages.

17 Apr 2004

Caffeine and children, some sound advice

Many adults are dependent on the caffeine in their morning coffee to get them going. But what about kids? Children who regularly drink soda, iced tea and other caffeine-containing beverages and foods may be getting too much. Find out how caffeine can be bad for your kids (and you) -- and how much is too much.

16 Apr 2004

Citrus soda culprit in patient’s medical mystery

It took a team of medical sleuths at Vanderbilt University Medical Center to get to the bottom of what was causing the 35-year-old to have abnormal blood chemistries during a post-transplant check up.

16 Apr 2004

New research findings in study of Rett Syndrome

Rudolf Jaenisch of the Whitehead Institute of Biomedical Research in Cambridge, MA reports in the April 6, 2004 online issue of the Proceedings of the National Academy of Sciences that introduction of the MeCP2 protein into post-mitotic nerve cells of MeCP2 mutant mice rescues the symptoms of Rett Syndrome. This raises the possibility that neurons are functionally normal in a newborn child and that neural dysfunction manifests itself only later due to prolonged MeCP2 deficiency. If correct, therapeutic strategies aimed at preventing the onset of Rett symptoms could be initiated at birth.

7 Apr 2004

Phase 3 study of drug teduglutide in patients with short bowel syndrome

Teduglutide is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Teduglutide has been shown in animal studies and previous human clinical trials to increase the size and number of these cells, thereby increasing the absorptive surface area of the intestines.

6 Apr 2004

Research shows giving Tourette Syndrome patients the drug levodopa normalizes brain activity

Scientists have known for years that abnormal activity involving a brain chemical called dopamine is somehow connected to the movements and vocalizations, or tics, associated with Tourette syndrome. Now neuroscience researchers at Washington University School of Medicine in St. Louis have found brain activity in these patients is abnormal during memory tasks, as well.

5 Apr 2004

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.

5 Apr 2004

New MRI Liver Contrast Agent Primovist(TM) Approved in Sweden

Schering AG Group, Germany has announced that the Swedish health authority MPA has granted marketing approval for its innovative liver imaging product Primovist(TM) (gadoxetic acid disodium). Primovist(TM) is designed for the detection and characterization of liver lesions by magnetic resonance imaging (MRI) including liver tumors, metastases as well as other malignant and benign lesions.

5 Apr 2004

Launch of thin needle syringe for multiple sclerosis treatment

A study conducted in Denmark showed that 86% of Rebif®-treated patients found that injections were easier and less painful using the new needle. The pre-filled syringe of Rebif® with the new needle is available in the same dosages as the previous version and will continue to carry the same indication. It is currently being launched in Europe and will be available worldwide by the end of 2004.

31 Mar 2004

Drug, Nembutal can suppress activity in colon cancer cells

A barbiturate once commonly used to treat anxiety may play a role in controlling the spread of colon cancer, say researchers from The University of Texas M. D. Anderson Cancer Center.

30 Mar 2004

Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors

Drugs approved for treatment of specific maladies sometimes show unexpected benefits. Researchers at the 95th annual meeting of the American Association for Cancer Research demonstrated highlighted how some drugs may one day offer previously unforeseen benefits for patients.

30 Mar 2004

Trial of new drug that may halt progression of Type I Diabetes

The results of a long-term clinical trial on a new drug designed to inhibit the progression of type I diabetes was announced at the International Diabetes Society meeting in Cambridge, England, March 29. The findings of the 18-month long clinical trial confirm the drug's efficacy in improving a diabetic's ability to produce insulin.

30 Mar 2004

New Australian collaboration to discover new drugs targeting epilepsy and anxiety

Bionomics Limited and Southern Cross University announced today that they had established a collaboration to discover new drugs targeting epilepsy and anxiety. Under the arrangement, Southern Cross University will provide Bionomics with extracts from its collection of Australian-based natural products, together with expertise in natural products chemistry.

30 Mar 2004

Cardiac sympathetic denervation the heart’s control from the sympathetic nervous system

Surgery to cut part of the nerves to the heart can reduce the risk of fainting or sudden death in young people with a heart rhythm disorder called long QT syndrome (LQTS), researchers reported in today’s rapid access issue of Circulation: Journal of the American Heart Association.

29 Mar 2004

Newly formed FAS Center for Systems Neuroscience

Harvard has long been recognized for its strength in neuroscience: Researchers in the Faculty of Arts and Sciences (FAS) are leaders in studies of behavior, perception, and brain development, while Harvard Medical School (HMS) was the first in the nation to establish a department of neurobiology.

29 Mar 2004

Cladribine Targeted to Become First Oral Therapy for Multiple Sclerosis

Serono and IVAX Corporation has announced positive results from two clinical trials with a new proprietary oral formulation of cladribine, a potential new treatment for multiple sclerosis (MS). The study results showed that the formulation of oral cladribine which has been developed by Serono and IVAX has met the targets for an orally administered product, with blood levels of cladribine in the expected therapeutic range. Efficacy studies of oral cladribine in MS patients are planned to start late 2004.

23 Mar 2004